Transcription of DOSING & ADMINISTRATION GUIDE - OCREVUS
{{id}} {{{paragraph}}}
Example: bachelor of science
DOSING & ADMINISTRATION GUIDE - OCREVUS
IndicationsOCREVUS is indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adultsContraindicationsOCREVUS is contraindicated in patients with active hepatitis B virus infection and in patients with a history of life-threatening infusion reaction to OCREVUS . The warnings and precautions for OCREVUS are infusion reactions, and infections, which include respiratory tract infections, herpes, progressive multifocal leukoencephalopathy (PML), and hepatitis B virus (HBV) reactivation. Additional warnings are possible increased risk of immunosuppressant effects with other immunosuppressants, reduction in immunoglobulins, and additional safety information, please see pages 15 through 17 and click here for full Prescribing Information and Medication & ADMINISTRATION GUIDEOCREVUS is supplied as a preservative-free, sterile solution in a single-dose vial contains 300 mg/10 mL of OCREVUS for intravenous is administered by intravenous infusion as a 600 mg dose every 6 months.
CONTRACEPTION Advise female patients of childbearing potential to use effective contraception while receiving OCREVUS and for 6 months after the last infusion of OCREVUS. PREGNANCY ... Both protocols use the same premedication, dose, formulation, and posttreatment monitoring.
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: